248 related articles for article (PubMed ID: 32653824)
1. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
2. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
3. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
[TBL] [Abstract][Full Text] [Related]
4. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
[TBL] [Abstract][Full Text] [Related]
5. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
6. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
Peng J; Li SJ; Fu X; Liu Y; Zhao XL
Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
8. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
9. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
10. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
Li YY; Wang YF; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
[TBL] [Abstract][Full Text] [Related]
11. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
[TBL] [Abstract][Full Text] [Related]
12. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Richon VM; Sandhoff TW; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
[TBL] [Abstract][Full Text] [Related]
14. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
Gong K; Xie J; Yi H; Li W
Biochem J; 2012 May; 443(3):735-46. PubMed ID: 22339555
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
16. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.
Chi Z; Gao H; Liu H; Wu B; Zhang B; Gu M; Yang W
Mol Med Rep; 2020 Feb; 21(2):936-944. PubMed ID: 31974619
[TBL] [Abstract][Full Text] [Related]
17. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
[TBL] [Abstract][Full Text] [Related]
19. Raman microspectroscopy detects epigenetic modifications in living Jurkat leukemic cells.
Poplineau M; Trussardi-Régnier A; Happillon T; Dufer J; Manfait M; Bernard P; Piot O; Antonicelli F
Epigenomics; 2011 Dec; 3(6):785-94. PubMed ID: 22126296
[TBL] [Abstract][Full Text] [Related]
20. Alterations in histone acetylation following exposure to
Tian XL; Lu X; Feng JB; Cai TJ; Li S; Tian M; Liu QJ
Radiat Environ Biophys; 2018 Aug; 57(3):215-222. PubMed ID: 29774413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
